UY35328A - Tratamiento de formas progresivas de esclerosis múltiple con laquinimod - Google Patents

Tratamiento de formas progresivas de esclerosis múltiple con laquinimod

Info

Publication number
UY35328A
UY35328A UY0001035328A UY35328A UY35328A UY 35328 A UY35328 A UY 35328A UY 0001035328 A UY0001035328 A UY 0001035328A UY 35328 A UY35328 A UY 35328A UY 35328 A UY35328 A UY 35328A
Authority
UY
Uruguay
Prior art keywords
laquinimod
multiple sclerosis
treatment
human subject
progressive forms
Prior art date
Application number
UY0001035328A
Other languages
English (en)
Inventor
Tarcic Nora
Dan Bar-Zohar
Hayardeny Liat
Yossi Gilgun Sherki
Gorfine Tali
Knappertz Volker
Sorani Ella
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35328(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY35328A publication Critical patent/UY35328A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

Un método para tratar un sujeto humano afectado por una forma progresiva de esclerosis múltiple, que comprende administrar periódicamente al sujeto humano una cantidad de laquinimod eficaz para tratar al sujeto humano. Laquinimod para usar en el tratamiento de un sujeto humano afectado por una forma progresiva de esclerosis múltiple. Composiciones farmacéuticas y envases que comprenden una cantidad eficaz de laquinimod para tratar una forma progresiva de esclerosis múltiple.
UY0001035328A 2013-02-15 2014-02-14 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod UY35328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03

Publications (1)

Publication Number Publication Date
UY35328A true UY35328A (es) 2014-09-30

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035328A UY35328A (es) 2013-02-15 2014-02-14 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod

Country Status (18)

Country Link
US (2) US20140235670A1 (es)
EP (1) EP2956137A4 (es)
JP (1) JP2016510343A (es)
KR (1) KR20150119227A (es)
CN (1) CN105163737A (es)
AU (1) AU2014216199A1 (es)
BR (1) BR112015019564A2 (es)
CA (1) CA2900503A1 (es)
CL (1) CL2015002181A1 (es)
EA (1) EA201591507A1 (es)
HK (2) HK1218251A1 (es)
IL (1) IL240014A0 (es)
MX (1) MX2015010296A (es)
PE (1) PE20151526A1 (es)
SG (1) SG11201505818WA (es)
TW (1) TW201442709A (es)
UY (1) UY35328A (es)
WO (1) WO2014127139A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140138694A (ko) 2012-02-03 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
WO2016059571A1 (en) * 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
EP3600553A4 (en) * 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
WO2007146248A2 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8138201B2 (en) * 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
EP2375900B1 (en) * 2008-12-11 2016-03-02 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
KR20120037477A (ko) * 2009-06-19 2012-04-19 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 다발경화증의 치료
NZ611628A (en) * 2010-12-07 2015-06-26 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
CN103781355A (zh) * 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与干扰素-β的组合治疗多发性硬化症
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
KR20150080509A (ko) * 2012-10-12 2015-07-09 테바 파마슈티컬 인더스트리즈 리미티드 다발성 경화증에서 시상 손상 감소를 위한 라퀴니모드
AU2015253330A1 (en) * 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

Also Published As

Publication number Publication date
CL2015002181A1 (es) 2016-06-03
IL240014A0 (en) 2015-09-24
BR112015019564A2 (pt) 2017-07-18
WO2014127139A1 (en) 2014-08-21
US20140235670A1 (en) 2014-08-21
TW201442709A (zh) 2014-11-16
US20180064702A1 (en) 2018-03-08
PE20151526A1 (es) 2015-11-20
MX2015010296A (es) 2016-05-05
SG11201505818WA (en) 2015-08-28
CN105163737A (zh) 2015-12-16
KR20150119227A (ko) 2015-10-23
JP2016510343A (ja) 2016-04-07
AU2014216199A1 (en) 2015-09-03
EP2956137A4 (en) 2016-08-03
EA201591507A1 (ru) 2015-12-30
HK1218254A1 (zh) 2017-02-10
HK1218251A1 (zh) 2017-02-10
EP2956137A1 (en) 2015-12-23
CA2900503A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
NI201600071A (es) Compuestos de inhibidor de autotaxina
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
PH12015502075A1 (en) Treatment of cataplexy
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
AR101740A1 (es) Terapia de combinación y composiciones
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
AR102871A1 (es) Métodos de tratamiento de fibrosis
EA201690446A1 (ru) Лечение множественной миеломы
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
EA201690445A1 (ru) Лечение рака
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
AR094809A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
IN2013MU03428A (es)
CR20140480A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
UY35748A (es) Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple
PH12020500472A1 (en) Autotaxin inhibitor compounds
AR085305A1 (es) Uso de la teriflunomida para el tratamiento del deterioro cognitivo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211105